New weight management drug begins safety testing in china
NCT ID NCT06916091
Summary
This early-stage study tested the safety and side effects of a single dose of eloralintide, an experimental weight management drug, in 30 Chinese adults with obesity or overweight. Researchers monitored participants for 10 weeks to see how their bodies handled the medication and what side effects occurred. The study focused on establishing basic safety before testing whether the drug actually helps with weight loss.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
Conditions
Explore the condition pages connected to this study.